The U.S. Department of Health has accepted an additional application for a new drug Xalkori from the company Pfizer. The drug is used to treat children with recurrent or refractory systemic anaplastic large cell lymphoma - ALCL. If approved, Xalkori will be the first drug to treat childhood lymphoma. The company expects a decision from the department in January 2021.